"The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
Renal: Dysuria, urinary retention. There have been rare reports of chemical cystitis or hemorrhagic cystitis following intravesical, but not parenteral administration of thiotepa (thiotepa (thiotepa injection) injection) .
Respiratory: Prolonged apnea has been reported when succinylcholine was administered prior to surgery, following combined use of thiotepa (thiotepa (thiotepa injection) injection) and other anticancer agents. It was theorized that this was caused by decrease of pseudocholinesterase activity caused by the anticancer drugs.
Special Senses: Conjunctivitis.
Reproductive: Amenorrhea, interference with spermatogenesis.
Read the Thiotepa (thiotepa injection) Side Effects Center for a complete guide to possible side effects
It is not advisable to combine, simultaneously or sequentially, cancer chemotherapeutic agents or a cancer chemotherapeutic agent and a therapeutic modality having the same mechanism of action. Therefore, thiotepa (thiotepa (thiotepa injection) injection) combined with other alkylating agents such as nitrogen mustard or cyclophosphamide or thiotepa (thiotepa (thiotepa injection) injection) combined with irradiation would serve to intensify toxicity rather than to enhance therapeutic response. If these agents must follow each other, it is important that recovery from the first agent, as indicated by white blood cell count, be complete before therapy with the second agent is instituted.
Other drugs which are known to produce bone-marrow depression should be avoided.
Last reviewed on RxList: 11/20/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Thiotepa Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.